Cargando…
Effect of Ranirestat on Sensory and Motor Nerve Function in Japanese Patients with Diabetic Polyneuropathy: A Randomized Double-Blind Placebo-Controlled Study
We conducted a 26-week oral-administration study of ranirestat (an aldose reductase inhibitor) at a once-daily dose of 20 mg to evaluate its efficacy and safety in Japanese patients with diabetic polyneuropathy (DPN). The primary endpoint was summed change in sensory nerve conduction velocity (NCV)...
Autores principales: | Satoh, Jo, Kohara, Nobuo, Sekiguchi, Kenji, Yamaguchi, Yasuyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4736957/ https://www.ncbi.nlm.nih.gov/pubmed/26881251 http://dx.doi.org/10.1155/2016/5383797 |
Ejemplares similares
-
Aldose reductase inhibitor ranirestat significantly improves nerve conduction velocity in diabetic polyneuropathy: A randomized double‐blind placebo‐controlled study in Japan
por: Sekiguchi, Kenji, et al.
Publicado: (2018) -
Ranirestat for the Management of Diabetic Sensorimotor Polyneuropathy
por: Bril, Vera, et al.
Publicado: (2009) -
Ranirestat Improved Nerve Conduction Velocities, Sensory Perception, and Intraepidermal Nerve Fiber Density in Rats with Overt Diabetic Polyneuropathy
por: Asano, Saeko, et al.
Publicado: (2019) -
Ranirestat Improves Electrophysiologic but not Clinical Measures of Diabetic Polyneuropathy: A Meta-Analysis
por: Dutta, Deep, et al.
Publicado: (2022) -
Effect of Ranirestat, a New Aldose Reductase Inhibitor, on Diabetic Retinopathy in SDT Rats
por: Toyoda, Fumihiko, et al.
Publicado: (2014)